Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 6 May 1994:
Vol. 264. no. 5160, pp. 833 - 835
DOI: 10.1126/science.8171337
Prev | Table of Contents | Next

Articles

Science, Vol 264, Issue 5160, 833-835
Copyright © 1994 by American Association for the Advancement of Science

articles

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells

C Renner, W Jung, U Sahin, R Denfeld, C Pohl, L Trumper, F Hartmann, V Diehl, R van Lier, and M Pfreundschuh

Medizinische Klinik und Poliklinik, Universitat des Saarlandes, Homburg, Germany.

Tumor immunotherapy should increase both the number of T cells that kill the tumor and the likelihood that those cells are activated at the tumor site. Bispecific monoclonal antibodies (Bi-mAbs) were designed that bound to a Hodgkin's tumor-associated antigen (CD30) on the tumor and to either CD3 or CD28 on the T cell. Immunodeficient mice were cured of established human tumors when mice were treated with both the CD3-CD30 and the CD28-CD30 Bi-mAbs and then given human peripheral blood lymphocytes that had been incubated with the CD3-CD30 Bi-mAb and cells that expressed CD30. The enrichment of human T cells within the tumor and the fact that established tumors can be cured may indicate in situ activation of both the T cell receptor and the costimulatory pathway.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
M. Schlapschy, M. Fogarasi, H. Gruber, O. Gresch, C. Schafer, Y. Aguib, and A. Skerra (2009)
Protein Eng. Des. Sel. 22, 175-188
   Abstract »    Full Text »    PDF »
Second-Generation Anti-Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation.
P. C.R. Emtage, A. S.Y. Lo, E. M. Gomes, D. L. Liu, R. M. Gonzalo-Daganzo, and R. P. Junghans (2008)
Clin. Cancer Res. 14, 8112-8122
   Abstract »    Full Text »    PDF »
Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
M. Schlapschy, H. Gruber, O. Gresch, C. Schafer, C. Renner, M. Pfreundschuh, and A. Skerra (2004)
Protein Eng. Des. Sel. 17, 847-860
   Abstract »    Full Text »    PDF »
Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
A. Lev, R. Noy, K. Oved, H. Novak, D. Segal, P. Walden, D. Zehn, and Y. Reiter (2004)
PNAS 101, 9051-9056
   Abstract »    Full Text »    PDF »
Induction of Human T Lymphocyte Cytotoxicity and Inhibition of Tumor Growth by Tumor-Specific Diabody-Based Molecules Secreted from Gene-Modified Bystander Cells.
B. Blanco, P. Holliger, R. G. Vile, and L. Alvarez-Vallina (2003)
J. Immunol. 171, 1070-1077
   Abstract »    Full Text »    PDF »
T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct.
T. Dreier, P. A. Baeuerle, I. Fichtner, M. Grun, B. Schlereth, G. Lorenczewski, P. Kufer, R. Lutterbuse, G. Riethmuller, P. Gjorstrup, et al. (2003)
J. Immunol. 170, 4397-4402
   Abstract »    Full Text »    PDF »
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy (2002)
Blood 100, 3155-3163
   Abstract »    Full Text »    PDF »
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.
P. Ruf and H. Lindhofer (2001)
Blood 98, 2526-2534
   Abstract »    Full Text »    PDF »
Regulatory CD4+CD25+ T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer.
E. Y. Woo, C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, and C. H. June (2001)
Cancer Res. 61, 4766-4772
   Abstract »    Full Text »    PDF »
Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 CD19 Tandem Diabody, and CD28 Costimulation.
B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, J. Schuhmacher, A. Benner, G. Moldenhauer, and M. Little (2000)
Cancer Res. 60, 4336-4341
   Abstract »    Full Text »
Treatment of Human B Cell Lymphoma Xenografts with a CD3 CD19 Diabody and T Cells.
B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, O. Christ, J. Schuhmacher, G. Strau{beta}, G. Moldenhauer, and M. Little (2000)
J. Immunol. 165, 888-895
   Abstract »    Full Text »    PDF »
Bypassing Immunization: Optimized Design of ""Designer T Cells"" against Carcinoembryonic Antigen (CEA)-expressing Tumors, and Lack of Suppression by Soluble CEA.
K. F. Nolan, C.-O. Yun, Y. Akamatsu, J. C. Murphy, S.-O. Leung, E. J. Beecham, and R. P. Junghans (1999)
Clin. Cancer Res. 5, 3928-3941
   Abstract »    Full Text »    PDF »
Anti-CD3/Anti-CD28 Monoclonal Antibody-Coated Suture Enhances the Immune Response of Patients With Head and Neck Squamous Cell Carcinoma.
T. Y. Shibuya, W.-Z. Wei, M. Zormeier, J. Ensley, W. Sakr, R. H. Mathog, R. J. Meleca, G. Yoo, C. H. June, B. Levine, et al. (1999)
Arch Otolaryngol Head Neck Surg 125, 1229-1234
   Abstract »    Full Text »    PDF »
Apoptosis of a Human Melanoma Cell Line Specifically Induced by Membrane-Bound Single-Chain Antibodies.
C. de Ines, B. Cochlovius, S. Schmidt, S. Kipriyanov, H.-J. Rode, and M. Little (1999)
J. Immunol. 163, 3948-3956
   Abstract »    Full Text »    PDF »
Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing.
R. Zeidler, G. Reisbach, B. Wollenberg, S. Lang, S. Chaubal, B. Schmitt, and H. Lindhofer (1999)
J. Immunol. 163, 1246-1252
   Abstract »    Full Text »    PDF »
Immunotherapy of Human Tumors with T-Cell-activating Bispecific Antibodies: Stimulation of Cytotoxic Pathways in Vivo.
S. Bauer, C. Renner, J.-P. Juwana, G. Held, S. Ohnesorge, K. Gerlach, and M. Pfreundschuh (1999)
Cancer Res. 59, 1961-1965
   Abstract »    Full Text »    PDF »
Immunotherapy of B-Cell Lymphoma With CD3x19 Bispecific Antibodies: Costimulation via CD28 Prevents "Veto" Apoptosis of Antibody-Targeted Cytotoxic T Cells.
P. T. Daniel, A. Kroidl, J. Kopp, I. Sturm, G. Moldenhauer, B. Dorken, and A. Pezzutto (1998)
Blood 92, 4750-4757
   Abstract »    Full Text »    PDF »
Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product.
H. M. Finney, A. D. G. Lawson, C. R. Bebbington, and A. N. C. Weir (1998)
J. Immunol. 161, 2791-2797
   Abstract »    Full Text »    PDF »
In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model.
J. De Jonge, C. Heirman, M. d. Veerman, S. Van Meirvenne, M. Moser, O. Leo, and K. Thielemans (1998)
J. Immunol. 161, 1454-1461
   Abstract »    Full Text »    PDF »
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody.
F. Hartmann, C. Renner, W. Jung, C. Deisting, M. Juwana, B. Eichentopf, M. Kloft, and M. Pfreundschuh (1997)
Blood 89, 2042-2047
   Abstract »    Full Text »    PDF »
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
F. Uckun, W. Evans, C. Forsyth, K. Waddick, L. Ahlgren, L. Chelstrom, A Burkhardt, J Bolen, and D. Myers (1995)
Science 267, 886-891
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)